A Pharmacoepidemiological Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice in Sweden.
Phase of Trial: Phase IV
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Acute coronary syndromes; Atrial fibrillation; Pulmonary embolism; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bayer
- 09 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 13 Jun 2015 New trial record